Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure

被引:56
|
作者
Chen, Harvey S. [1 ]
Joo, Dong Jin [1 ,2 ]
Shaheen, Mohammed [1 ]
Li, Yi [1 ,3 ]
Wang, Yujia [1 ,3 ]
Yang, Jian [1 ,3 ]
Nicolas, Clara T. [1 ]
Predmore, Kelly [1 ]
Amiot, Bruce [1 ]
Michalak, Gregory [4 ]
Mounajjed, Taofic [5 ]
Fidler, Jeff [4 ]
Kremers, Walter K. [1 ,6 ]
Nyberg, Scott L. [1 ]
机构
[1] Mayo Clin, William J von Liebig Ctr Transplantat & Clin Rege, 200 First St, Rochester, MN 55905 USA
[2] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
[3] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
[4] Mayo Clin, Dept Radiol, Rochester, MN USA
[5] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[6] Mayo Clin, Dept Biostat, Rochester, MN USA
关键词
PORTAL-VEIN LIGATION; ALBUMIN DIALYSIS; HEPATIC-FAILURE; RESECTION; DEVICE; PIGS; HEPATECTOMY; EXCHANGE;
D O I
10.1002/hep.30184
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio-artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild-type large white swine (20 kg-30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24-48 hours after hepatectomy: Group1-standard medical therapy (SMT, n = 6); Group2-SMT plus bio-artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3-SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200-g group survived to 90 hours (P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200-g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200-g group compared with the SMT (P < 0.01) and 0-g (P < 0.01) groups. Ki-67 staining showed increased positive staining at 48 hours following hepatectomy (P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
引用
收藏
页码:329 / 342
页数:14
相关论文
共 50 条
  • [32] LONG TERM STABILITY AND INDUCIBILITY OF PRIMARY HEPATOCYTES CULTURED IN A SPHEROID RESERVOIR BIOARTIFICIAL LIVER.
    Brophy, Colleen M.
    Luebke-Wheeler, Jennifer L.
    Amiot, Bruce P.
    Remmel, Rory P.
    Nyberg, Scott L.
    LIVER TRANSPLANTATION, 2008, 14 (07) : S188 - S188
  • [33] Successful pregnancy after porcine bioartificial liver treatment and liver transplantation for fulminant hepatic failure
    Nyberg, SL
    Hay, EJ
    Ramin, KD
    Rosen, CB
    LIVER TRANSPLANTATION, 2002, 8 (02) : 169 - 170
  • [34] Treatment of severe liver failure with a bioartificial liver
    Chen, SC
    Mullon, C
    Kahaku, E
    Watanabe, F
    Hewitt, W
    Eguchi, S
    Middleton, Y
    Arkadopoulos, N
    Rozga, J
    Solomon, B
    Demetriou, AA
    BIOARTIFICIAL ORGANS: SCIENCE, MEDICINE, AND TECHNOLOGY, 1997, 831 : 350 - 360
  • [35] MARS treatment in posthepatectomy liver failure
    van de Kerkhove, MP
    de Jong, KP
    Rijken, AM
    de Pont, ACJM
    van Gulik, TM
    LIVER INTERNATIONAL, 2003, 23 : 44 - 51
  • [36] The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model
    Enosawa, Shin
    Miyashita, Tomoyuki
    Saito, Tomohiro
    Omasa, Takeshi
    Matsumura, Toshiharu
    CELL TRANSPLANTATION, 2006, 15 (10) : 873 - 880
  • [37] In vitro assessment of a novel porcine liver slice-filled bioartificial liver (BAL) for dialysis of liver failure patients
    Behrsing, Holger
    Tam, Jennifer
    Park, Young
    Yun, Hyoung
    Do, Andy
    Gray, Brad
    Zhao, Delai
    Gropper, Charles
    Jung, Jaeho
    Gish, Robert
    Mcguire, Brendan
    Panoskaltsis-Mortari, Angela
    Lau, George K. K.
    Lim, Young-Suk
    Lee, Han Chu
    Suh, Dong-Jin
    Park, Sung-Soo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A91 - A91
  • [38] Liver transplantation as a lifesaving procedure for posthepatectomy liver failure and iatrogenic liver injuries
    Thorsen, Trygve
    Solheim, Jon Magnus
    Labori, Knut Jorgen
    Line, Pal-Dag
    Aandahl, Einar Martin
    LANGENBECKS ARCHIVES OF SURGERY, 2019, 404 (03) : 301 - 308
  • [39] Usefulness of Liver Stiffness Measurement for the Prediction of Posthepatectomy Liver Failure
    Taura, Kojiro
    Koyama, Yukinori
    Tanabe, Kazutaka
    Yamamoto, Gen
    Ishii, Takamichi
    Hatano, Etsuro
    Uemoto, Shinji
    HEPATOLOGY, 2012, 56 : 515A - 516A
  • [40] A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure
    Selden, Clare
    Bundy, James
    Erro, Eloy
    Puschmann, Eva
    Miller, Malcolm
    Kahn, Delawir
    Hodgson, Humphrey
    Fuller, Barry
    Gonzalez-Molina, Jordi
    Le Lay, Aurelie
    Gibbons, Stephanie
    Chalmers, Sherri
    Modi, Sunil
    Thomas, Amy
    Kilbride, Peter
    Isaacs, Agnes
    Ginsburg, Richard
    Ilsley, Helen
    Thomson, David
    Chinnery, Galya
    Mankahla, Ncedile
    Loo, Lizel
    Spearman, C. Wendy
    SCIENTIFIC REPORTS, 2017, 7